Seeking Alpha

Seattle Genetics (SGEN +4%) gains despite posting a mixed second quarter. Total revenue surged...

Seattle Genetics (SGEN +4%) gains despite posting a mixed second quarter. Total revenue surged on narrower losses and higher sales of its lymphoma drug Adcetris, but revenue growth still fell short of analyst expectations, largely due to lofty expectations by the Street on Adcetris sales numbers.

Check out Seeking Alpha’s new Earnings Center »

From other sites
Comments (2)
  • hooridian
    , contributor
    Comments (17) | Send Message
     
    Analysts expectations are not always realistic.
    9 Aug 2012, 04:51 PM Reply Like
  • Scrying Biotech
    , contributor
    Comments (1907) | Send Message
     
    It's also difficult to anticipate the myriad of things that can go wrong. In this case, the drug (Adcetris) worked too well and patients were progressed sooner than expected on to other remedies. The drug however, continues to gain favor among physicians and therefore will prescribed more often. In 2013, it will be prescribed for other uses as well.
    24 Aug 2012, 05:15 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs